Patient safety and antimicrobial stewardship (ams)

Ochakovskaya I.N., Ni O.G., SHabanova N.Е.

The development of antimicrobial resistance by bacteria associated with increased mortality has determined it necessary to adopt programs for rationalizing antibiotic use. However, introduction of antibiotic restriction policy to clinical practice meets opposition of doctors, who consider these measures as being contrary to hospitalized patients’ interests. In the article actions of Antimicrobial Stewardship are considered not only as a tool to combat the growth of antibiotic resistance and the preservation of antibacterial drugs for future generations, but, first and foremost, as a program that ensures the safety of patient treatment.

1. World Alliance for Patient Safety: forward programme. WHO; 2005. (In Russ).

2. Gusarov VG, Zamyatin MN, Teplykh BA, et al. Antibiotikorezistentnost’: puti resheniya problemy v mnogoprofil’nom stacionare. Bulletin of Pirogov National Medical & Surgical Center. 2014;9(3):97–101. (In Russ).

3. Dyachenko SV, Slobodenyuk EV, Dyachenko VG. Organizatsiya antibakterial’noi terapii rasprostranennykh zabolevanii. Uchebnoe posobie. Khabarovsk: Izd. centr DVGMU; 2010. 475 p. (In Russ).

4. Eliseeva EV, Gainullina YuI, Gel’tser BI. Upravlenie kachestvom v sfere primeneniya antibakterial’nykh preparatov. Vladivostok: Dal’nauka; 2010. 180 p. (In Russ).

5. Zhukova EV. Sovremennoe sostoyanie problemy antibiotikorezistentnosti i epidemiologicheskii nadzor za ustoichivost’yu mikroorganizmov k antibakterial’nym preparatam. Poliklinika. 2015;(2-2):44–47. (In Russ).

6. Litovkina MI. Bezopasnost’ patsientov v mezhdunarodnykh pravovykh dokumentakh. In: Voprosy sovremennoi yurisprudentsii: sbornik po materialam XX mezhdunarodnoi nauchno-prakticheskoi konferentsii. Novosibirsk: SibAK; 2013. pp. 113–122. (In Russ).

7. Nauchno-issledovatel’skii institut antimikrobnoi khimioterapii. Nauchnyi otchet o rezul’tatakh issledovaniya antibiotikorezistentnosti bakterial’nykh vozbuditelei nozokomial’nykh infektsii v otdeleniyakh s intensivnym ispol’zovaniem antibiotikov v statsionarakh Rossii (ReVANSH). Smolensk, 2009. (In Russ).

8. Polyak MS. Osnovy antibiotikoterapii. St. Petersburg: NICF; 2003. 32 p. (In Russ).

9. Programma SKAT (Strategiya Kontrolya Antimikrobnoi Terapii) pri okazanii statsionarnoi meditsinskoi pomoshchi: metodicheskie rekomendatsii. Ed by S.V. Yakovlev, M.V. Zhuravleva, D.N. Protsenko, V.B. Beloborodov. Moscow: Pero; 2016. 100 p. (In Russ).

10. Strategiya i taktika primeneniya antimikrobnykh sredstv v lechebnykh uchrezhdeniyakh Rossii. Rossiiskie natsional’nye rekomendatsii. Moscow; 2012. 96 p. (In Russ).

11. Yakovlev SV, Suvorova MP, Beloborodov VB, et al. Safety: achieving a new standard for care multicentre study of the prevalence and clinical value of hospital-acquired infections in emergency hospitals of Russia: ERGINI Study. Antibiotics and chemoterapy. 2016;61(5–6):32–42. (In Russ).

12. Allerberger F, Gareis R, Jindrák V, Struelens MJ. Antibiotic stewardship implementation in the EU: the way forward. Expert Rev Anti Infect Ther. 2009;7(10): 1175–1183. doi: 10.1586/eri.09.96.

13. Armstrong GL, Conn LA, Pinner RW. Trends in infectious disease mortality in the United States during the 20th century. JAMA. 1999;281(1):61–66. doi: 10.1001/jama.281.1.61.

14. Asensio A, Oliver A, González-Diego P, et al. Outbreak of a multiresistant K. pneumoniae strain in an intensive care unit: antibiotic use as a risk factor for colonization and infection. Clin Infect Dis. 2000;30(1):55–60. doi: 10.1086/313590.

15. Brennan TA, Leape LL, Laird NM, et al. Incidence of adverse events and negligence in hospitalized patients. Results of the Harvard Medical Practice Study I. N Engl J Med. 1991;324(6):370–376. doi: 10.1056/NEJM199102073240604.

16. Charani E, Cooke J, Holmes A. Antibiotic stewardship programmes – what’s missing? J Antimicrob Chemother. 2010;65(11):2275–2277. doi: 10.1093/jac/dkq357.

17. Cosgrove S. The relationship between antimicrobial resistance and patient outcomes, mortality, length of hospital stay, and health care costs. Clin Infect Dis. 2006; 42 Suppl 2:S82–89. doi: 10.1086/499406.

18. Dellit TH, Owens RC, McGowan JE, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007; 44(2):159–177. doi: 10.1086/510393.

19. Drew RH. Antimicrobial stewardship programs: how to start and steer a successful program. J Manag Care Pharm. 2009;15(2 Suppl):S18–23. doi: 10.18553/jmcp.2009.15.s2.18.

20. Duguid M, Cruickshank M, editors. Antimicrobial stewardship in Australian hospitals [Internet]. Canberra: Biotext; 2011. 208 p. [cited 2019 Sep 12].

21. Gould IM. A review of the role of antibiotic policies in the control of antibiotic resistance. J Antimicrob Chemother. 1999;43(4):459–465. doi: 10.1093/jac/43.4.459.

22. Gould IM. Stewardship of antibiotic use and resistance surveillance: the international scene. J Hosp Infect. 1999;43 Suppl:S253–260. doi: 10.1016/s0195-6701(99) 90095-6.

23. Institute of Medicine (US) Committee on Data Standards for Patient Safety; Aspden P, Corrigan JM, Wolcott J, Erickson SM, editors. Patient safety: achieving a new standard for care. Washington, DC: National Academies Press (US); 2004. 528 p.

24. Jha AK, Prasopa-Plaizier N, Larizgoitia I, et al. Patient safety research: an overview of the global evidence. Qual Saf Health Care. 2010;19(1):42–47. doi: 10.1136/qshc.2008.029165.

25. Laundy M, Gilchrist M, Whitney L, editors. Antimicrobial stewardship. Oxford, UK: Oxford University Press; 2016. pp. 168–230. doi: 10.1093/med/9780198758792. 001.0001.

26. MacDougall C, Polk RE. Antimicrobial stewardship programs in health care systems. Clin Microbiol Rev. 2005;18(4):638–656. doi: 10.1128/cmr.18.4.638-656.2005.

27. Maragakis LL, Perencevich EN, Cosgrove SE. Clinical and economic burden of antimicrobial resistance. Expert Rev Anti Infect Ther. 2008;6(5):751–763. doi: 10.1586/14787210.6.5.751.

28. Di Bartolomeo M. The Luxembourg Declaration on Patient Safety: a political comment. Ital J Public Health. 2005;2(3-4):9–10. doi: 10.2427/5956

29. Owens RC Jr, Rice L. Hospital-based strategies for combating resistance. Clin Infect Dis. 2006;42 (4):173–181. doi: 10.1086/500664.

30. Patel D, Macdougall C. How to make antimicrobial stewardship work: practical considerations for hospitals of all sizes. Hosp Pharm. 2010;45(11):10–21. doi: 10.1310/hpj4511-s10.

31. Paterson DL. The role of antimicrobial management programs in optimizing antibiotic prescribing within hospitals. Clin Infect Dis. 2006;42(2):90–95. doi: 10.1086/499407.

32. Lamanna A, Moro G, Riss M, Vannini I, editors. Patient’s Rights in Europe: Civic information on the Implementation of the European Charter of Patient’s Rights [Internet]. Final Report, 2007 [cited 2019 Sep 12].

33. Safdar N, Maki DG. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida. Ann Intern Med. 2002;136(11):834–844. doi: 10.7326/0003-4819-136-11-200206040-00013.

34. Saurina G, Quale JM, Manikal VM, et al. Antimicrobial resistance in Enterobacteriaceae in Brooklyn, NY: epidemiology and relation to antibiotic usage patterns. J Antimicrob Chemother. 2000;45(6):895–898. doiI: 10.1093/jac/45.6.895.

35. Shehab N, Patel PR, Srinivasan A, Budnitz DS. Emergency department visits for antibiotic-associated adverse events. Clin Infect Dis. 2008;47(6):735–743. doi: 10.1086/591126.

36. Tamma PD, Holmes A, Ashley ED. Antimicrobial stewardship: another focus for patient safety? Curr Opin Infect Dis. 2014;27(4):348–355.doi: 10.1097/QCO.0000000000000077.

37. Thomas EJ, Studdert DM, Burstin HR, et al. Incidence and types of adverse events and negligent care in Utah and Colorado. Med Care. 2000;38(3):261–271. doi: 10.1097/00005650-200003000-00003.

38. Valiquette L, Cossette B, Garant MP, et al. Impact of a reduction in the use of high-risk antibiotics on the course of an epidemic of Clostridium difficile associated disease caused by the hypervirulent NAP1/027 strain. Clin Infect Dis. 2007;45(2):112–121. doi: 10.1086/519258.

39. World Health Organization. WHO Global Strategy for Containment of Antimicrobial Resistance [Internet]. Switzerland: WHO; 2001 [cited 2019 Sep 12].

40. World Health Organization. World Alliance for Patient Safety: forward programme 2008-2009 [Internet]. 1st ed. France: WHO; 2008 [cited 2019 Sep 12].